Development of analytical method for simultaneous determination of five rodent unique bile acids in rat plasma using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1002, Issue , 2015, Pages 399-410

  Minato, Kouichi ^a   Suzuki, Masanori ^a   Nagao, Hidenori ^a   Suzuki, Ryota ^a   Ochiai, Hiroyuki ^a  

^a Grelan Pharmaceutical Co   (Japan)

Author keywords

Bile acid; Biomarker; Liver injury; Muricholic acid; Rat Plasma; UPLC TOF MS

Indexed keywords

AMINO ACIDS; BIOMARKERS; BODY FLUIDS; CALIBRATION; CARBON; CHROMATOGRAPHY; DIAGNOSIS; DRUG PRODUCTS; INDUCTIVELY COUPLED PLASMA; ISOTOPES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ALGEBRA; METABOLIC ENGINEERING; NEGATIVE IONS; QUALITY CONTROL; RATS; SPECTROMETRY;

BILE ACID; LIVER INJURIES; LOWER LIMIT OF QUANTIFICATIONS; RAT PLASMA; SIMULTANEOUS DETERMINATIONS; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPLC-TOF-MS;

CHLOROACETIC ACID;

1 NAPHTHYL ISOTHIOCYANATE; ACTIVATED CARBON; ALPHA MURICHOLIC ACID; ALPHA TAURINE ALPHA MURICHOLIC ACID; BETA MURICHOLIC ACID; BETA TAURINE BETA MURICHOLIC ACID; BILE ACID; CARBON TETRACHLORIDE; FLUTAMIDE; OMEGA MURICHOLIC ACID; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID BLOOD LEVEL; CALIBRATION; CHOLESTASIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; LIMIT OF QUANTITATION; LIVER INJURY; LIVER TOXICITY; MALE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RAT; RELIABILITY; SENSITIVITY AND SPECIFICITY; STEATOSIS; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; BLOOD; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROCEDURES; REPRODUCIBILITY; SPRAGUE DAWLEY RAT; VALIDATION STUDY;

ANIMALS; BILE ACIDS AND SALTS; CALIBRATION; CHROMATOGRAPHY, LIQUID; FLUTAMIDE; MALE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS;

EID: 84941313038     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2015.08.047     Document Type: Article

References (42)

1. Russell D.W. The enzymes regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 2003, 72:137-174.
2. Botham K.M., Boyd G.S. The metabolism of chenodeoxycholic acid to β-muricholic acid in rat liver. Eur. J. Biochem. 1983, 134:191-196.
3. Hofmann A.F., Hagey L.R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 2008, 65:2461-2483.
4. Franklund C.V., de Prada P., Hylemon P.B. Purification and characterization of a microbial, NADP-dependent bile acid 7 alpha-hydroxysteroid dehydrogenase. J. Biol. Chem. 1990, 265:98942-99849.
5. Sharma R., Long A., Giles J.F. Advances in bile acid medicinal chemistry. Curr. Med. Chem. 2011, 18:4029-4052.
6. Sayin S.I., Wahlström A., Felin J., Jäntti S., H-UM, arschall K.B., amberg B.A., ngelin,T H., yotylainen M.O., resič F.B., ackhed Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013, 17:225-235.
7. Aoki M., Konya Y., Takagi T., Umemura K., Sogame Y., Katsuamata T., Komuro S. Metabolomic investigation of cholestasis in a rat model using ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 25:1847-1852.
8. Goto J., Hasegawa K., Nambara T., Iida T. Studies on steroids. CCLIV. Gas chromatographic-mass spectrometric determination of 4- and 6-hydroxylated bile acids in human urine with negative ion chemical ionization detection. J. Chromatogr. 1992, 574:1-7.
9. Eyssen H.J., Parmentier G.G., Mertens J.A. Sulfate bile acids in germ-free and conventional mice. Eur. J. Biochem. 1976, 66:507-514.
10. Szabo G., Bala S., Petrasek J., Gattu A. Gut-liver axis and sensing microbes. Dig. Dis. 2010, 28:737-744.
11. Abu-Shanab A., Quigley E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:691-701.
12. Quigley E.M.M., Marsh M.N., Shaffer J.L., Markin R.S. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993, 104:286-301.
13. Terjung B., Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a leaky gut?. Clin. Rev. Allergy Immunol. 2009, 36:40-51.
14. Want E.J., Coen M., Masson P., Keun H.C., Pearce J.T.M., Reily M.D., Robertson D.G., Rohde C.M., Hol E.H., es J.C.L., indon R.S.P., lumb A.K.N., icholson Ultra performance liquid chromatography-mass spectrometry profiling of bile acid metabolites in biofluids: application to experimental toxicology studies. Anal. Chem. 2010, 82:5282-5289.
15. Plumb R.S., Granger J.H., Stumpf C.L., Johnson K.A., Smith B.W., Gaulitz S., Wilson I.D., Castro-Perez J. A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst 2005, 130:844-849.
16. Wilson I.D., Nicholson J.K., Castro-Perez J., Granger J.H., Johnson K.A., Smith B.W., Plumb R.S. High resolution ultra performance liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studied. J. Proteome Res. 2005, 4:591-598.
17. Zelenza E., Dunn W.B., Broadhurst D., Francis-McIntyre S., Carroll K.M., Begley P., O'Hagan S., Knowles J.D., Halsall A., Consortium H.U.S.E.R.M.E.T., Wilson I.D., Kell D.B. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal. Chem. 2009, 81:1357-1364.
18. Mori N., Yokooji T., Kamio Y., Murakami T. Increases intestinal absorption of mizoribine an immunosuppressive agent, in cholestatic rats. Pharmazie 2010, 65:457-460.
19. Asakawa N., Koyama M., Hashimoto Y., Yamashita K., Esumi Y., Takaichi M., Seki H., Harada T., Honda N. Studies on the metabolic fate of flutamide (2): absorption, distribution and excretion after single oral administration in rats. Xenobiotic Metabol. Dispos. 1995, 10:454-463.
20. Seftel A. Comparison of the pharmacological effects of a novel selective androgen receptor modulator (SARM), the 5α-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia (BPH). J. Urol. 2005, 173:1279.
21. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM) (2001) Guidance for industry, bioanalytical method validation.
22. Boone L., Meyer D., Cusick P., Ennulat D., Bolliger A.P., Everds N., Meador V., Elliott G., Honor D., Bounous D., Jordan H. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet. Clin. Pathol. 2005, 34:182-188.
23. Olson H.H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
24. Ennulat D., Magid-Slav M., Rehm S., Tatsuoka K.S. Diagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat. Toxicol. Sci. 2010, 116:397-412.
25. Bouchier I.A., Pennington C.R. Serum bile acids in hepatobiliary disease. Gut 1978, 19:492-496.
26. Bremmelgaard A., Sjovall J. Bile acid profiles in urine of patients with liver diseases. Eur. J. Clin. Invest. 1979, 9:341-348.
27. Balkman C.E., Center S.A., Randolph J.F., Trainor D., Warner K.L., Crawford M.A., Adachi K., Erb H.N. Evaluation of urine sulfated and nonsulfated bile acids as a diagnostic test for liver disease in dogs. J. Am. Vet. Med. Assoc. 2003, 222:1368-1375.
28. Hofmann A.F. The enterohepatic of bile acids in mammals: form and functions. Front. Biosci. 2009, 14:2584-2598.
29. Kawai H., Kudo N., Kawashima Y., Mitsumoto A. Efficacy of urine bile acid as a non-invasive indicator of liver damage in rats. J. Toxicol. Sci. 2009, 34:27-38.
30. Chiang J.Y.L. Regulation of bile acid synthesis: pathways, nucleat receptors, and mechanisms. J. Hepatol. 2004, 40:539-551.
31. García-Cañaveras J.C., Donato M.T., Castell J.V., Lahoz A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J. Lipid Res. 2012, 53:2231-2241.
32. Han J., Liu Y., Wang R., Yang J., Ling V., Borchers C.H. Metabolic profiling of bile acids in human and mouse blood by LC-MS/MS in combination with phospholipid-depletion solid-phase extraction. Anal. Chem. 2015, 87:1127-1136.
33. Becker B.A., Plaa G.L. The nature of alpha-naphthylisothiocyanate-induced cholestasis. Toxicol. Appl. Pharmacol. 1965, 7:680-685.
34. Plaa G.L., Priestly B.G. Intrahepatic cholestasis induced by drugs and chemicals. Pharmacol Rev. 1976, 28:207-273.
35. Ding L., Zhang B., Zhan C., Yang L.l., Wang Z. Danning tablets attenuates α-naphthylisothiocyanate-induced cholestasis by modulating the expression of transporters and metabolic enzymes. BMC Complement. Altern. Med. 2014, 14:249.
36. Castillo T., Koop D.R., Kamimura S., Triadafilopoulos G., Tsukamoto H. Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. Hepatology 1992, 16:992-996.
37. Manibusan M.K., Odin M., Eastmond D.A. Postulated carbon tetrachloride mode of action: a review. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2007, 25:185-209.
38. Yamazaki M., Miyake M., Sato H., Masutomi N., Tsutsui N., Adam K.P., Alexander D.C., Lawton K.A., Milburn M.V., Ryals J.A., Wulff J.E., Guo L. Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol. Appl. Pharmacol. 2013, 268:79-89.
39. Wysowski D.K., Fourcroy J.L. Flutamide hepatotoxicity. J. Urol. 1996, 155:209-212.
40. Thole Z., Manso G., Salgueiro E., Revuelta P., Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol. Int. 2004, 73:289-295.
41. Manso G., Thole Z., Salgueiro E., Revuelta P., Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol. Drug Saf. 2006, 15:253-259.
42. Watanabe T., Miyake M., Shimizu T., Kamezawa M., Masutomi N., Shimura T., Ohashi R. Utility of bilirubins and bile acids as endogenous biomarkers for the inhibition of hepatic transporters. Drug Metab. Dispos. 2015, 15:253-259.